Cardiovascular Complications of Chimeric Antigen Receptor T-Cell Therapy: The Cytokine Release Syndrome and Associated Arrhythmias.
CAR T-cell therapy
arrhythmias
cardiotoxicity
cardiovascular complications
chimeric antigen receptor
cytokine release syndrome
Journal
Journal of immunotherapy and precision oncology
ISSN: 2590-017X
Titre abrégé: J Immunother Precis Oncol
Pays: United States
ID NLM: 101768397
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
24
03
2020
accepted:
28
05
2020
entrez:
6
6
2022
pubmed:
20
7
2020
medline:
20
7
2020
Statut:
epublish
Résumé
In recent years, cancer treatment has evolved, and new therapies have been introduced with significant improvement in prognosis. The immunotherapies stand out owing to their efficacy and remission rate. Chimeric antigen receptor (CAR) T-cell therapy is a part of this new era of therapies. Chimeric antigen receptor T-cell therapy is a form of adoptive cellular therapy that uses a genetically encoded CAR in modified human T cells to target specific tumor antigens in a nonconventional, non-major histocompatibility complex (MHC) protein presentation. Chimeric antigen receptor T-cell therapy successfully identifies tumor antigens and through activation of T cells destroys tumoral cells. It has been found to efficiently induce remission in patients who have been previously treated for B-cell malignancies and have persistent disease. As the use of this novel therapy increases, its potential side effects also have become more evident, including major complications like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Cytokine release syndrome is a major systemic inflammatory process as a result of massive cytokine production by the proliferating and activated CAR T cells in which multiple interleukins and immune cells contribute to the inflammatory response. Cytokine release syndrome has been associated with cardiovascular life-threatening complications including hypotension, shock, tachycardia, arrhythmias, left ventricular dysfunction, heart failure, and cardiovascular death. Arrhythmias, among its major complications, vary from asymptomatic prolonged corrected QT interval (QTc) to supraventricular tachycardia, atrial fibrillation, flutter, and ventricular arrhythmias like Torsade de pointes. This article focuses on the cardiovascular complications and arrhythmias associated with CRS and CAR T-cell therapy.
Identifiants
pubmed: 35663258
doi: 10.36401/JIPO-20-10
pmc: PMC9165578
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
113-120Informations de copyright
© Innovative Healthcare Institute.
Déclaration de conflit d'intérêts
Conflict of Interest: None.
Références
Sci Transl Med. 2014 Feb 19;6(224):224ra25
pubmed: 24553386
Circulation. 2005 Jun 7;111(22):2881-8
pubmed: 15927979
Biol Blood Marrow Transplant. 2018 Aug;24(8):1590-1595
pubmed: 29772353
J Am Coll Cardiol. 2019 Dec 24;74(25):3153-3163
pubmed: 31856973
Herz. 2019 Apr;44(2):121-129
pubmed: 30729269
Front Cell Dev Biol. 2019 Oct 11;7:233
pubmed: 31681766
Nat Med. 2018 Jan;24(1):20-28
pubmed: 29155426
J Clin Oncol. 2015 Feb 20;33(6):540-9
pubmed: 25154820
Mol Cancer. 2018 Feb 15;17(1):32
pubmed: 29448937
Cardiol Clin. 2019 Nov;37(4):385-397
pubmed: 31587780
Blood. 2016 Jun 30;127(26):3321-30
pubmed: 27207799
Curr Oncol Rep. 2019 Mar 27;21(5):38
pubmed: 30919158
Europace. 2003 Jul;5(3):251-5
pubmed: 12842639
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Eur Heart J. 2004 Jul;25(13):1100-7
pubmed: 15231367
Blood. 2013 Dec 12;122(25):4129-39
pubmed: 24055823
Clin Cancer Res. 2020 Apr 1;26(7):1541-1554
pubmed: 31672768
Circulation. 1997 Nov 18;96(10):3542-8
pubmed: 9396453
Sci Transl Med. 2013 Aug 7;5(197):197ra103
pubmed: 23926201
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
Onco Targets Ther. 2019 Sep 30;12:8015-8022
pubmed: 31686857
J Clin Oncol. 2016 Apr 1;34(10):1112-21
pubmed: 26811520
Lancet. 2015 Feb 7;385(9967):517-528
pubmed: 25319501
J Am Coll Cardiol. 2019 Dec 24;74(25):3099-3108
pubmed: 31856966
JAMA. 2004 Apr 14;291(14):1720-9
pubmed: 15082699
Oncologist. 2018 Aug;23(8):943-947
pubmed: 29622697
J Am Heart Assoc. 2019 Aug 20;8(16):e011006
pubmed: 31423933
Blood. 2017 Nov 23;130(21):2295-2306
pubmed: 28924019
Cytokine. 2018 Nov;111:171-177
pubmed: 30172113
Curr Oncol Rep. 2018 Apr 11;20(6):44
pubmed: 29644505
J Biol Chem. 2004 Apr 2;279(14):13289-92
pubmed: 14973143
Front Cardiovasc Med. 2015 May 27;2:26
pubmed: 26798623
Crit Care. 2017 Apr 14;21(1):89
pubmed: 28407743
Mol Ther Oncolytics. 2016 Apr 20;3:16011
pubmed: 27626062
Eur Heart J. 2018 Jun 7;39(22):2063-2069
pubmed: 29584915
Curr Oncol Rep. 2019 Jan 21;21(1):4
pubmed: 30666425
Ann Thorac Surg. 2006 Sep;82(3):1057-61
pubmed: 16928536
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638
pubmed: 30592986
N Engl J Med. 2019 May 2;380(18):1726-1737
pubmed: 31042825
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62
pubmed: 28925994
J Cardiovasc Electrophysiol. 2004 Nov;15(11):1271-6
pubmed: 15574177
Heart. 2017 Nov;103(22):1821-1829
pubmed: 28490617
Hematol Oncol. 2019 Jun;37 Suppl 1:48-52
pubmed: 31187535
Blood. 2010 Nov 18;116(20):4099-102
pubmed: 20668228
Medicine (Baltimore). 2019 Oct;98(43):e17572
pubmed: 31651858
Blood. 2013 Aug 8;122(6):863-71
pubmed: 23770775
J Clin Oncol. 2017 Jun 1;35(16):1803-1813
pubmed: 28291388
J Cardiothorac Vasc Anesth. 2006 Feb;20(1):51-6
pubmed: 16458214
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Nat Rev Cardiol. 2015 Apr;12(4):230-43
pubmed: 25622848
Am J Physiol Heart Circ Physiol. 2006 May;290(5):H2098-107
pubmed: 16339842
Heart. 2006 Mar;92(3):316-20
pubmed: 15923280
J Intensive Care. 2015 Nov 11;3:48
pubmed: 26566443
Circulation. 2006 Sep 12;114(11):1146-50
pubmed: 16952983